The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients

Cancer Cell International

Massoud Houshmand¹  Nasrin Moazami⁵  Behnam Kamalidehghan⁴  Forouzandeh Fereidooni³  Reza Mahdian²  Massoud Ghaffarpour⁵ 

[1] Medical Genetics Department, National Institute for Genetic Engineering & Biotechnology, Tehran, Iran;Biotechnology Research Center, Molecular Medicine Department, Pasteur Institute of Iran, Tehran, Iran;National Cancer Institute, Imam Khomeini Hospitals Complex, Tehran University of Medical Science, Tehran, Iran;Pharmacy Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;Iranian Research Organization for Science and Technology, Tehran, Iran

关键词: Breast cancer;    ATPase8;    ATPase6;    MtDNA;   

Others  :  792257
DOI  :  10.1186/1475-2867-14-21

 received in 2013-07-20, accepted in 2014-02-20,  发布年份 2014

【 摘 要 】

Background

Breast cancer is the most common malignancy in women throughout the world. Mitochondria play important roles in cellular energy production, free radical generation and apoptosis. Identification of mitochondrial DNA mutations and/or polymorphisms as cancer biomarkers is rapidly developing in molecular oncology research.

Methods

In this study, the DNA alterations of the mitochondrial ATPase 6 and 8 genes were investigated in 49 breast cancer patients using PCR amplification and direct DNA sequencing on mtDNA. A possible association between these variants and tumorigenesis was assessed. Furthermore, the impact of non-synonymous substitutions on the amino acid sequence was evaluated using the PolyPhen-2 software.

Results

Twenty eight distinct somatic mitochondrial DNA variants were detected in tumor tissues but not in the corresponding adjacent non-tumor tissues. Among these variants, 9 were observed for the first time in breast cancer patients. The mtDNA variants of A8384 (T7A), T8567C (I14T), G8572A (G16S), A9041G (H172R) and G9055A (A177T) showed the most significant effects probably due to damaging changes to the resulting protein. Furthermore, non-synonymous amino acid changing variants were more frequent in the ATPase6 gene compared to the ATPase8 gene.

Conclusion

Our results showed that the ATPase6 gene is more susceptible to variations in breast cancer and may play an important role in tumorigenesis by changing the energy metabolism level in cancer cells.

【 授权许可】

   
2014 Ghaffarpour et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Most frequent cancers; Women [updated; 15/5/2013;cited];available from;http://globocan.iarc.fr/factsheets/cancers/breast.asp webcite
• [2]Movahedi MHS, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, Esmail-Akbari M: Survival rate of breast cancer based on geographical variation in Iran, a national study. Iran Red Crescent Med J 2012, 14(12):798-804.
• [3]Anderson SBA, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG: Sequence and organization of the human mitochondrial genome. Nature 1981, 290:457-464.
• [4]Wallace DC: a mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annul Rev Gene 2005, 39:359-408.
• [5]Czarnecka AMKW, Krawczyk T, Scinska A, Kukwa A, Cappello F: Mitochondrial DNA mutations in cancer from bench to bedside. Front Biosci 2010, 15:437-463.
• [6]Lu JSL, Bai Y: Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Research 2009, 19:802-815.
• [7]William C, Copeland JTW, Johnson FM, Penta JS: Mitochondrial DNA Alterations in Cancer. Cancer Investigation 2002, 20(4):554-566.
• [8]Chatterjee ADS, Sidransky D: Mitochondrial subversion in cancer. Cancer Prev Res 2011, 4:638-649.
• [9]William C, Copeland JTW, Johnson FM, Penta JS: Mitochondrial DNA Alterations in Cancer. Cancer Investigation 2002, 20(4):12.
• [10]Shidara YYK, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S: Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 2005, 65(5):1655-1663.
• [11]Amuthan GBG, Zhang SY, Klein-Szanto A, Vijayasarathy C: Avadhani NG.; 20(8), 1910–20.: Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. Embo J 2001, 20(8):10.
• [12]Yu MZY, Shi Y, Ning L, Yang Y, Wei X, Zhang N, Hao X, Niu R: Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life 2007, 59(7):450-456.
• [13]Matsuyama WNM, Wakimoto J, Hirotsu Y, Kawabata M, Osame M: Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer. Hum Mutat 2003, 21(4):441-443.
• [14]Uzawa KBT, Uchida F, Yamatoji M, Kasamatsu A, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H, Tanzawa H: Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma. Oncotarget 2012, 3(7):670-677.
• [15]Kulawiec MSJ, Ericson NG, Wanagat J, Bielas JH: Generation, function, and prognostic utility of somatic mitochondrial DNA mutations in cancer. Environ Mol Mutagen 2010, 51(5):427-439.
• [16]Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, Lechleiter J, Naylor SL, Deng JJ, Lu J: A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 2009, 18(9):1578-1589.
• [17]Desler CMM, Singh KK, Rasmussen LJ: The Importance of Mitochondrial DNA in Aging and Cancer. Journal of Aging Research 2011,  . doi:10.4061/2011/407536
• [18]Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J-I: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320(5876):661-664.
• [19]Dasgupta SKR, Westra WH, Califano JA, Ha PK, Sidransky D, Koch WM: Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients. Cancer Prev Res 2010, 3:1205-1211.
• [20]Ishikawa KIH, Takenaga K, Hayashi J: Regulation of metastasis; mitochondrial DNA mutations have appeared on stage. J Bioenerg Biomembr 2012, 44(6):639.
• [21]Kulawiec MOK, Singh KK: Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther 2009, 8(14):1378-1385.
• [22]Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK: AJCC Cancer Staging Atlas: A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook (Greene, AJCC Cancer Staging Atlas). New York: Springer; 2012.
• [23]Houshmand MKS, Etemad Ahari S, Moin M, Bahar M, Zamani A: Investigation of tRNA and ATPase 6/8 gene mutations in Iranian ataxia telangiectasia patients. Arch Med Sci 2011, 7(3):523-527.
• [24]Adzhubei IASS, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010, 7(4):248-249.
• [25]Jonckheere An ISJAM, Rodenburg Richard JT: Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis 2012, 35:221-225.
• [26]Amuthan GBG, Zhang SY, Klein-Szanto A, Vijayasarathy C, Avadhani NG: Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. Embo J 2001, 20(8):1910-1920.
• [27]Matsuyama SXQ, Velours J, Reed JC: The Mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1998, 1(3):327-336.
• [28]Chen GFCF, Hong BF, Chan LW, Chan PS: Mitochondrial DNA mutations in chemical carcinogeninduced rat bladder and human bladder cancer. Oncol Rep 2004, 12(2):463-471.
• [29]Zhu WQW, Bradley P, Wessel A, Puckett CL, Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid Carcinogenesis. Carcinogenesis 2005, 26(1):145-152.
• [30]Tan DJBR, Wong LJ: Comprehensive Scanning of Somatic Mitochondrial DNA Mutations in Breast Cancer. Cancer Res 2002, 62(4):972-976.
• [31]Czarnecka AMKA, Krawczyk T, Zdrozny M, Arnold RS, Bartnik E, Petros JA: Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. Oncol Rep 2010, 23(2):531-535.
• [32]Bai RK LS, Covarrubias D, Liu A, Wong LJ: mitochondrial genetic background modifies breast cancer risk. Cancer Res 2007, 67(10):4683-4687.
• [33]Kirches E: Mitochondrial and nuclear genes of mitochondrial components in cancer. Curr Genomics 2009, 10(4):281-292.
• [34]Sawabe M, Tanaka M, Chida K, Arai T, Nishigaki Y, Fuku N, Mieno MN, Kuchiba A, Tanaka N: Mitochondrial haplogroups A and M7a confer a genetic risk for coronary atherosclerosis in the Japanese elderly: an autopsy study of 1,536 patients. Journal of Atherosclerosis and Thrombosis 2011, 18(2):166-175.
• [35]DeHaan C, Habibi-Nazhad B, Yan E, Salloum N, Parliament M, Allalunis-Turner J: Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Mol Cancer 2004, 3:19. BioMed Central Full Text
• [36]Taylor RWBM, Borthwick GM, Gospel A, Chinnery PF, Samuels DC, Taylor GA, Plusa SM, Needham SJ, Greaves LC, Kirkwood TB, Turnbull DM: Mitochondrial DNA mutations in human colonic crypt stem cells. J Clin Invest 2003, 112(9):1351-1360.
• [37]Houshmand MMM, Kuchekian N, Noohi F, Nozar G, Zamani A: Is 8860 variation a rare polymorphism or associated as a secondary effect in HCM disease? Arch Med Sci 2011, 7(2):242-426.
• [38]Aikhionbare FO KM, Carey D, Okoli J, Go R: Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression? Mol Cancer 2004, 3:30. BioMed Central Full Text
• [39]Aikhionbare FO MS, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E: Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog 2007, 6:1. BioMed Central Full Text
• [40]Mehrabi SAJ, Adams G Jr, Grizzle W, Yao X, Aikhionbare FO: A sequence variant in colorectal adenomatous polyps. Diagn Pathol 2010, 5:66. BioMed Central Full Text
• [41]Fauser SLJ, Besch D, Leo-Kottler B: Sequence analysis of the complete mitochondrial genome in patients with Leber’s hereditary optic neuropathy lacking the three most common pathogenic DNA mutations. Biochem Biophys Res Commun 2002, 295:342-347.
• [42]Mostafaie N, Rossmanith W, Hombauer H, Dechat T, Raffelsberger T, Bauer K, Worofka B, Kittl E, Hofmann J, Hejtman M: Mitochondrial genotype and risk for Alzheimer’s disease: Cross-sectional data from the Vienna-Transdanube-Aging “VITA” study. J Neural Transm 2004, 111(9):1155-1165.
• [43]Kirk RFR, Amos W, Cooper G, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC: Mitochondrial genetic analyses suggest selection against maternal lineages in bipolar affective disorder. Am J Hum Genet 1999, 65:508-518.
• [44]Tan DJCJ, Chen WL, Agress LJ, Yeh KT, Wang B, Wong LJ: Novel heteroplasmic frameshift and missense somatic mitochondrial DNA mutations in oral cancer of betel quid chewers. Genes Chromosomes Cancer 2003, 37:186-194.
• [45]Wang LBW, de Andrade M, Boardman LA, Cunningham JM, Thibodeau SN, Petersen GM: Mitochondrial genetic polymorphisms and pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 17(7):1455-1459.
• [46]Guney AIED, Tavukcu HH, Koc G, Kirac D, Ulucan K, Javadova D, Turkeri L: Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. Genet Test Mol Biomarkers 2012, 16(7):672-679.
• [47]van der Walt JM NK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Tajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM: Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease. Am J Hum Genet 2003, 72(4):804-812.
• [48]Petros JA BA, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC: mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005, 102(3):719-724.